NCT01103635 2020-04-07
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
Clinical Trials
8 trialsNCT02665416 2020-04-07
Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02304393 2019-12-13
A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT02225002 2018-08-28
Phase 1, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01456585 2018-08-27
Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT02760797 2018-05-22
A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT00607048 2017-03-27
Dose Finding Study Of CP-870,893, An Immune System Stimulating Antibody, In Combination With Paclitaxel And Carboplatin For Patients With Metastatic Solid Tumors
Hoffmann-La Roche
Phase 1 Completed
NCT01008527 2015-09-24
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed